Journal profile · Biotechnology & Applied Microbiology
Expert Opinion on Biological Therapy
ISSN 1471-2598 · eISSN 1744-7682 · Taylor and Francis Ltd. · ENGLAND · Bimonthly · Founded 2001
Expert Opinion on Biological Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.99; JCR Q2 (journal website); hybrid open access; APC charged, amount not published; median 81 days to acceptance (105 articles, last 24 months); community-reported acceptance: fairly easy; 115 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Opinion on Biological Therapy is published by Taylor and Francis Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immunotherapy and Immune Responses, Virus-based gene therapy research and Monoclonal and Polyclonal Antibodies Research, together about 25.5% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Expert Opinion on Biological Therapy [ISSN 1471-2598]; [e-ISSN 1744-7682] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers in biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. Expert Opinion on Biological Therapy aims to address the needs of scientists and managers in the healthcare and biopharmaceutical industries, and others closely involved in the development and application of biological therapies for the treatment of human disease. Articles focus on the following key areas: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Please note that the journal does not publish case reports or case series. Letters to the Editor should discuss articles previously published in the journal. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Opinion on Biological Therapy, part of the Expert Collection brand. Authors can choose to publish gold open access in this journal and may choose to publish using our Accelerated Publication services. For any pre-submission enquiries, please contact the Commissioning Editor.
From the journal's Aims & Scope
Research area (LetPub): Biotechnology & Applied Microbiology
Editor-in-chief Thomas CiullaPublisher website
Editorial board by country: none in mainland China; most named United States 21, Italy 9, Hong Kong, China 3, Australia 3, United Kingdom 2 (51 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immunotherapy and Immune ResponsesImmunology and Microbiology8.8%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology8.7%
- Monoclonal and Polyclonal Antibodies ResearchMedicine8%
- CAR-T cell therapy researchMedicine6.9%
- Cancer Immunotherapy and BiomarkersMedicine5.6%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology5.2%
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology4.8%
- Mesenchymal stem cell researchMedicine4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: yes
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCurrent ContentsPublisher website
Other: Index Medicus, Biotechnology Citation Index
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.99LetPub ·
- Impact factor (publisher) 2025
- 4Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.1Publisher website ·
- CiteScore 2026-06
- 6.5LetPub ·
- CiteScore (publisher) 2025
- 6.5Publisher website ·
- SJR 2026-06
- 1.05LetPub ·
- SJR (publisher) 2025
- 1.05Publisher website ·
- SNIP 2026-06
- 0.79LetPub ·
- SNIP (publisher) 2025
- 0.79Publisher website ·
- h-index
- 75LetPub ·
- h-index
- 122OpenAlex ·
- i10-index
- 2,625OpenAlex ·
- 2-year mean citedness
- 3.39OpenAlex ·
- Self-citation rate
- 2.5%LetPub ·
- Share of gold OA articles
- 7.1%LetPub ·
Volume
- Articles per year
- 93LetPub ·
- Downloads per year (publisher)
- 441,000Publisher website ·
- Downloads per year (publisher) 2025
- 441,000Publisher website ·
Articles by year OpenAlex count · 4,025 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 109 | 42 | 28 |
| 2025 | 115 | 45 | 336 |
| 2024 | 146 | 55 | 890 |
| 2023 | 111 | 46 | 1,250 |
| 2022 | 111 | 49 | 1,986 |
| 2021 | 133 | 44 | 2,399 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
81 daysMedian, submission to acceptance · P25–P75 57 days – 105 days
- Acceptance to online
- median 7 days (105 articles)
- Submission to online
- median 92 days
- Sample
- 105 articles with submission and acceptance dates (261 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 25%Publisher website ·
- Acceptance rate (publisher) 2025
- 25%Publisher website ·
- Submission to first decision
- 3 daysPublisher website ·
- Submission to first decision 2025
- 3 daysPublisher website ·
- First decision after review
- 39 daysPublisher website ·
- First decision after review 2025
- 39 daysPublisher website ·
- Acceptance to publication
- 8 daysPublisher website ·
- Acceptance to publication 2025
- 8 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
Expert Opinion on Biological Therapy is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discov…
Source ↗Publisher website ·- Peer review
Double-anonymous peer review by independent, expert referees after suitability assessment by the Editorial Team. Model summary
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2001
- ISSN
- 1471-2598
- Electronic ISSN
- 1744-7682
- Latest issue on the website
- Volume 26, Issue 9 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Expert Opinion on Biological Therapy
What CAS zone is Expert Opinion on Biological Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Opinion on Biological Therapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Biotechnology & Applied Microbiology / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Opinion on Biological Therapy?
The latest impact factor listed by LetPub is 3.99; CiteScore 6.5, h-index 122.
How long does peer review take at Expert Opinion on Biological Therapy?
Based on the dates recorded on 105 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 81 days (interquartile range 57–105 days); authors report an average review time of 3–8 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 25% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Expert Opinion on Biological Therapy in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Expert Opinion on Biological Therapy based?
Of the 51 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (21), Italy (9) and Hong Kong, China (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Expert Opinion on Biological Therapy?
According to LetPub and DOAJ records, Expert Opinion on Biological Therapy is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Expert Opinion on Biological Therapy open access, and what is the APC?
Expert Opinion on Biological Therapy is a hybrid journal. For open-access publication: APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .